215 results on '"Enric, Domingo"'
Search Results
2. Single-cell AI-based detection and prognostic and predictive value of DNA mismatch repair deficiency in colorectal cancer
- Author
-
Marta Nowak, Faiz Jabbar, Ann-Katrin Rodewald, Luciana Gneo, Tijana Tomasevic, Andrea Harkin, Tim Iveson, Mark Saunders, Rachel Kerr, Karin Oein, Noori Maka, Jennifer Hay, Joanne Edwards, Ian Tomlinson, Owen Sansom, Caroline Kelly, Francesco Pezzella, David Kerr, Alistair Easton, Enric Domingo, Viktor H. Koelzer, David N. Church, Bengt Glimelius, Ismail Gogenur, Emma Jaeger, Hannah Morgan, Clare Orange, Claire Palles, and Campbell Roxburgh
- Subjects
colorectal cancer ,mismatch repair deficiency ,microsatellite instability ,AI ,digital pathology ,Medicine (General) ,R5-920 - Abstract
Summary: Testing for DNA mismatch repair deficiency (MMRd) is recommended for all colorectal cancers (CRCs). Automating this would enable precision medicine, particularly if providing information on etiology not captured by deep learning (DL) methods. We present AIMMeR, an AI-based method for determination of mismatch repair (MMR) protein expression at a single-cell level in routine pathology samples. AIMMeR shows an area under the receiver-operator curve (AUROC) of 0.98, and specificity of ≥75% at 98% sensitivity against pathologist ground truth in stage II/III in two trial cohorts, with positive predictive value of ≥98% for the commonest pattern of somatic MMRd. Lower agreement with microsatellite instability (MSI) testing (AUROC 0.86) reflects discordance between MMR and MSI PCR rather than AIMMeR misclassification. Analysis of the SCOT trial confirms MMRd prognostic value in oxaliplatin-treated patients; while MMRd does not predict differential benefit of chemotherapy duration, it correlates with difference in relapse by regimen (PInteraction = 0.04). AIMMeR may help reduce pathologist workload and streamline diagnostics in CRC.
- Published
- 2024
- Full Text
- View/download PDF
3. Identification and validation of a machine learning model of complete response to radiation in rectal cancer reveals immune infiltrate and TGFβ as key predictorsResearch in context
- Author
-
Enric Domingo, Sanjay Rathee, Andrew Blake, Leslie Samuel, Graeme Murray, David Sebag-Montefiore, Simon Gollins, Nicholas West, Rubina Begum, Susan Richman, Phil Quirke, Keara Redmond, Aikaterini Chatzipli, Alessandro Barberis, Sylvana Hassanieh, Umair Mahmood, Michael Youdell, Ultan McDermott, Viktor Koelzer, Simon Leedham, Ian Tomlinson, Philip Dunne, Francesca M. Buffa, Timothy S. Maughan, Francesca Buffa, Geoffrey Higgins, Christopher Holmes, Timothy Maughan, Gillies McKenna, James Robineau, Philip Quirke, Matthew Seymour, Richard Kennedy, Mark Lawler, Manuel Salto-Tellez, Peter Campbell, Claire Hardy, Simon Bach, Andrew Beggs, Jean-Baptiste Cazier, Gary Middleton, Dion Morton, Celina Whalley, Louise Brown, Richard Kaplan, Richard Wilson, Richard Adams, Richard Sullivan, Paul Harkin, Steven Walker, Jim Hill, Chieh-Hsi Wu, and Dennis Horgan
- Subjects
Rectal neoplasms ,Radiotherapy ,Precision medicine ,Prediction ,TGFβ ,Immune response ,Medicine ,Medicine (General) ,R5-920 - Abstract
Summary: Background: It is uncertain which biological features underpin the response of rectal cancer (RC) to radiotherapy. No biomarker is currently in clinical use to select patients for treatment modifications. Methods: We identified two cohorts of patients (total N = 249) with RC treated with neoadjuvant radiotherapy (45Gy/25) plus fluoropyrimidine. This discovery set included 57 cases with pathological complete response (pCR) to chemoradiotherapy (23%). Pre-treatment cancer biopsies were assessed using transcriptome-wide mRNA expression and targeted DNA sequencing for copy number and driver mutations. Biological candidate and machine learning (ML) approaches were used to identify predictors of pCR to radiotherapy independent of tumour stage. Findings were assessed in 107 cases from an independent validation set (GSE87211). Findings: Three gene expression sets showed significant independent associations with pCR: Fibroblast-TGFβ Response Signature (F-TBRS) with radioresistance; and cytotoxic lymphocyte (CL) expression signature and consensus molecular subtype CMS1 with radiosensitivity. These associations were replicated in the validation cohort. In parallel, a gradient boosting machine model comprising the expression of 33 genes generated in the discovery cohort showed high performance in GSE87211 with 90% sensitivity, 86% specificity. Biological and ML signatures indicated similar mechanisms underlying radiation response, and showed better AUC and p-values than published transcriptomic signatures of radiation response in RC. Interpretation: RCs responding completely to chemoradiotherapy (CRT) have biological characteristics of immune response and absence of immune inhibitory TGFβ signalling. These tumours may be identified with a potential biomarker based on a 33 gene expression signature. This could help select patients likely to respond to treatment with a primary radiotherapy approach as for anal cancer. Conversely, those with predicted radioresistance may be candidates for clinical trials evaluating addition of immune-oncology agents and stromal TGFβ signalling inhibition. Funding: The Stratification in Colorectal Cancer Consortium (S:CORT) was funded by the Medical Research Council and Cancer Research UK (MR/M016587/1).
- Published
- 2024
- Full Text
- View/download PDF
4. Image-based consensus molecular subtyping in rectal cancer biopsies and response to neoadjuvant chemoradiotherapy
- Author
-
Maxime W. Lafarge, Enric Domingo, Korsuk Sirinukunwattana, Ruby Wood, Leslie Samuel, Graeme Murray, Susan D. Richman, Andrew Blake, David Sebag-Montefiore, Simon Gollins, Eckhard Klieser, Daniel Neureiter, Florian Huemer, Richard Greil, Philip Dunne, Philip Quirke, Lukas Weiss, Jens Rittscher, Tim Maughan, and Viktor H. Koelzer
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract The development of deep learning (DL) models to predict the consensus molecular subtypes (CMS) from histopathology images (imCMS) is a promising and cost-effective strategy to support patient stratification. Here, we investigate whether imCMS calls generated from whole slide histopathology images (WSIs) of rectal cancer (RC) pre-treatment biopsies are associated with pathological complete response (pCR) to neoadjuvant long course chemoradiotherapy (LCRT) with single agent fluoropyrimidine. DL models were trained to classify WSIs of colorectal cancers stained with hematoxylin and eosin into one of the four CMS classes using a multi-centric dataset of resection and biopsy specimens (n = 1057 WSIs) with paired transcriptional data. Classifiers were tested on a held out RC biopsy cohort (ARISTOTLE) and correlated with pCR to LCRT in an independent dataset merging two RC cohorts (ARISTOTLE, n = 114 and SALZBURG, n = 55 patients). DL models predicted CMS with high classification performance in multiple comparative analyses. In the independent cohorts (ARISTOTLE, SALZBURG), cases with WSIs classified as imCMS1 had a significantly higher likelihood of achieving pCR (OR = 2.69, 95% CI 1.01–7.17, p = 0.048). Conversely, imCMS4 was associated with lack of pCR (OR = 0.25, 95% CI 0.07–0.88, p = 0.031). Classification maps demonstrated pathologist-interpretable associations with high stromal content in imCMS4 cases, associated with poor outcome. No significant association was found in imCMS2 or imCMS3. imCMS classification of pre-treatment biopsies is a fast and inexpensive solution to identify patient groups that could benefit from neoadjuvant LCRT. The significant associations between imCMS1/imCMS4 with pCR suggest the existence of predictive morphological features that could enhance standard pathological assessment.
- Published
- 2024
- Full Text
- View/download PDF
5. Accounting for intensity variation in image analysis of large‐scale multiplexed clinical trial datasets
- Author
-
Anja L Frei, Anthony McGuigan, Ritik RAK Sinha, Mark A Glaire, Faiz Jabbar, Luciana Gneo, Tijana Tomasevic, Andrea Harkin, Tim J Iveson, Mark Saunders, Karin Oein, Noori Maka, Francesco Pezella, Leticia Campo, Jennifer Hay, Joanne Edwards, Owen J Sansom, Caroline Kelly, Ian Tomlinson, Wanja Kildal, Rachel S Kerr, David J Kerr, Håvard E Danielsen, Enric Domingo, TransSCOT Consortium, David N Church, and Viktor H Koelzer
- Subjects
digital pathology ,fluorescence microscopy ,image analysis ,Pathology ,RB1-214 - Abstract
Abstract Multiplex immunofluorescence (mIF) imaging can provide comprehensive quantitative and spatial information for multiple immune markers for tumour immunoprofiling. However, application at scale to clinical trial samples sourced from multiple institutions is challenging due to pre‐analytical heterogeneity. This study reports an analytical approach to the largest multi‐parameter immunoprofiling study of clinical trial samples to date. We analysed 12,592 tissue microarray (TMA) spots from 3,545 colorectal cancers sourced from more than 240 institutions in two clinical trials (QUASAR 2 and SCOT) stained for CD4, CD8, CD20, CD68, FoxP3, pan‐cytokeratin, and DAPI by mIF. TMA slides were multi‐spectrally imaged and analysed by cell‐based and pixel‐based marker analysis. We developed an adaptive thresholding method to account for inter‐ and intra‐slide intensity variation in TMA analysis. Applying this method effectively ameliorated inter‐ and intra‐slide intensity variation improving the image analysis results compared with methods using a single global threshold. Correlation of CD8 data derived by our mIF analysis approach with single‐plex chromogenic immunohistochemistry CD8 data derived from subsequent sections indicates the validity of our method (Spearman's rank correlation coefficients ρ between 0.63 and 0.66, p ≪ 0.01) as compared with the current gold standard analysis approach. Evaluation of correlation between cell‐based and pixel‐based analysis results confirms equivalency (ρ > 0.8, p ≪ 0.01, except for CD20 in the epithelial region) of both analytical approaches. These data suggest that our adaptive thresholding approach can enable analysis of mIF‐stained clinical trial TMA datasets by digital pathology at scale for precision immunoprofiling.
- Published
- 2023
- Full Text
- View/download PDF
6. Joint Prediction of Response to Therapy, Molecular Traits, and Spatial Organisation in Colorectal Cancer Biopsies.
- Author
-
Ruby Wood, Enric Domingo, Korsuk Sirinukunwattana, Maxime W. Lafarge, Viktor H. Koelzer, Timothy S. Maughan, and Jens Rittscher
- Published
- 2023
- Full Text
- View/download PDF
7. Pulmonary vascular pressure respiratory swings in COPD and ILD candidates for lung transplantation: Large but different
- Author
-
Juan C. Grignola, Alvaro Calabuig, Pedro Trujillo, Carles Bravo, Fernando Azpiroz, Manuel López Messeguer, and Enric Domingo
- Subjects
chronic lung disease ,esophageal pressure ,lung transplantation ,pulmonary vascular pressure respiratory swing ,transmural pulmonary vascular pressure ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 ,Diseases of the respiratory system ,RC705-779 - Abstract
Abstract We analyzed the effect of respiratory swings on interpreting intravascular pulmonary vascular pressures (PVPs) in chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) candidates for lung transplantation (LTx) and the role of the alterations in pulmonary function tests on the dynamic respiratory variations. Twenty‐eight consecutive patients were included. All patients underwent a complete hemodynamic study (right atrial, mean pulmonary arterial, and pulmonary arterial occlusion pressures [RAP, mPAP, and PAOP]‐) and pulmonary function testing (force vital capacity [FVC], forced expiratory volume in the first second [FEV1], and residual volume [RV]). A subgroup of 10 patients underwent simultaneous esophageal pressure (PES). All hemodynamic parameters and PES were collected during apnea after an unforced expiration (ee) and during spontaneous breathing averaging five respiratory cycles (mrc). The respiratory swing (osc) was estimated as the difference between maximum–minimum values of pressures during the respiratory cycle. Intravascular RAPee, mPAPee, and PAOPee were higher than mrc values (p
- Published
- 2024
- Full Text
- View/download PDF
8. Enhancing Local Context of Histology Features in Vision Transformers.
- Author
-
Ruby Wood, Korsuk Sirinukunwattana, Enric Domingo, Alexander Sauer, Maxime W. Lafarge, Viktor H. Koelzer, Timothy S. Maughan, and Jens Rittscher
- Published
- 2022
- Full Text
- View/download PDF
9. A proliferative subtype of colorectal liver metastases exhibits hypersensitivity to cytotoxic chemotherapy
- Author
-
Liam F. Spurr, Carlos A. Martinez, Rohan R. Katipally, Soumya C. Iyer, Sian A. Pugh, John A. Bridgewater, John N. Primrose, Enric Domingo, Timothy S. Maughan, Michael I. D’Angelica, Mark Talamonti, Mitchell C. Posner, Philip P. Connell, Ralph R. Weichselbaum, and Sean P. Pitroda
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Personalized treatment approaches for patients with limited liver metastases from colorectal cancer are critically needed. By leveraging three large, independent cohorts of patients with colorectal liver metastases (n = 336), we found that a proliferative subtype associated with elevated CIN70 scores is linked to immune exclusion, increased metastatic proclivity, and inferior overall survival in colorectal liver metastases; however, high CIN70 scores generate a therapeutic vulnerability to DNA-damaging therapies leading to improved treatment responses. We propose CIN70 as a candidate biomarker to personalize systemic treatment options for patients with metastatic colorectal cancer. These findings are potentially broadly applicable to other human cancers.
- Published
- 2022
- Full Text
- View/download PDF
10. Seguimiento clínico del stent coronario largo no cónico de sirolimus en el mundo real en lesiones de novo. Registro Billar
- Author
-
Enric Domingo Ribas, Josep Guindo, Ramón Calviño Santos, Imanol Otaegui, Joan Antoni Gómez, Xavier Carrillo Suárez, Juan Sánchez, Leire Andraka, Alfonso Torres, Juan Casanova-Sandoval, Raymundo Ocaranza Sánchez, Javier León Jiménez, Juan Francisco Muñoz, Ramiro Trillo Nouche, Mónica Fuertes, and Bruno García del Blanco
- Subjects
Angioplastia coronaria ,Stents farmacoactivos ,Stents largos no cónicos ,Internal medicine ,RC31-1245 - Abstract
RESUMEN Introducción y objetivos: Las lesiones coronarias largas y difusas, cuando se tratan percutáneamente, requieren a menudo superposición de los stents, que se asocia a una mayor tasa de reestenosis. Por otro lado, el adelgazamiento progresivo de las arterias dificulta el tratamiento de las lesiones largas. En este estudio se analizan la seguridad y la eficacia clínica de los stents liberadores de sirolimus largos no cónicos (> 36 mm) para el tratamiento de lesiones largas de novo en un escenario real. Métodos: Estudio prospectivo, no aleatorizado, multicéntrico, con 696 pacientes consecutivos con implantación de stent BioMime largo no cónico para el tratamiento de lesiones coronarias de novo largas y difusas. El criterio de valoración de seguridad fueron los eventos adversos cardiovasculares mayores en el seguimiento, definidos como la combinación de muerte cardiaca, infarto de miocardio, necesidad de nueva revascularización en la misma lesión guiada por la clínica, trombosis del stent o hemorragia mayor a los 12 meses. Resultados: De los 696 pacientes incluidos, el 38,79% eran diabéticos. La edad media fue de 64,6 ± 14 años y el 80% eran varones. La indicación de revascularización fue un síndrome coronario agudo en el 63,1%. Se identificaron 899 lesiones, de las que 742 se trataron con éxito con stents BioMime (37-40-44-48 mm). La incidencia acumulada de eventos adversos cardiovasculares mayores fue del 8,1% a los 12 meses, con un 2,09% de muertes de causa cardiaca, un 1,34% de infartos de miocardio y un 0,5% de trombosis del stent. Conclusiones: El presente estudio confirma la seguridad y el buen perfil clínico a 12 meses del stent BioMime largo no cónico para el tratamiento de lesiones coronarias de novo largas y difusas, por lo que debe considerarse un tratamiento seguro y eficaz para este tipo de lesiones en la práctica clínica habitual.
- Published
- 2022
- Full Text
- View/download PDF
11. Clinical follow-up of long nontapered sirolimus-eluting coronary stent in real-world patients with de novo lesions. The Billar registry
- Author
-
Enric Domingo Ribas, Josep Guindo, Ramón Calviño Santos, Imanol Otaegui, Joan Antoni Gómez, Xavier Carrillo Suárez, Juan Sánchez, Leire Andraka, Alfonso Torres, Juan Casanova-Sandoval, Raymundo Ocaranza Sánchez, Javier León Jiménez, Juan Francisco Muñoz, Ramiro Trillo Nouche, Mónica Fuertes, and Bruno García del Blanco
- Subjects
Coronary angioplasty ,Drug-eluting stent ,Nontapered stents ,Medicine - Abstract
ABSTRACT Introduction and objectives: Coronary lesions with stent overlapping are associated with higher neointimal proliferation that leads to more restenosis. Furthermore, the tapering of coronary arteries is a major challenge when treating long coronary lesions. This study attempted to assess the safety and clinical level of performance of long nontapered sirolimus-eluting coronary stent systems (> 36 mm) to treat long and diffused de novo coronary lesions in real-world scenarios. Methods: This was a prospective, non-randomized, multicentre study that included 696 consecutive patients treated with the long nontapered BioMime sirolimus-eluting coronary stent system in long and diffused de novo coronary lesions. The safety endpoint was major adverse cardiovascular events defined as a composite of cardiac death, myocardial infarction, clinically driven target lesion revascularization, stent thrombosis, and major bleeding at the 12-month follow-up. Results: Of a total of 696 patients, 38.79% were diabetic. The mean age of all the patients was 64.6 ± 14 years, and 80% were males. The indication for revascularization was acute coronary syndrome in 63.1%. A total of 899 lesions were identified out of which 742 were successfully treated with long BioMime stents (37 mm, 40 mm, 44 mm, and 48 mm). The cumulative incidence of major adverse cardiovascular events was 8.1% at the 12-month follow-up including cardiac death (2.09%), myocardial infarction (1.34%), and total stent thrombosis (0.5%). Conclusions: This study confirms the safety and good performance of long nontapered BioMime coronary stents to treat de novo coronary stenosis. Therefore, it can be considered a safe and effective treatment for long and diffused de novo coronary lesions in the routine clinical practice.
- Published
- 2022
- Full Text
- View/download PDF
12. Complement downregulation promotes an inflammatory signature that renders colorectal cancer susceptible to immunotherapy
- Author
-
Enric Domingo, Sahar El Aidy, Gary Hardiman, Carsten Krieg, Lukas M Weber, Bruno Fosso, Marinella Marzano, Monica M Olcina, Khalil Mallah, Mark D Robinson, and Silvia Guglietta
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background and aims The role of inflammatory immune responses in colorectal cancer (CRC) development and response to therapy is a matter of intense debate. While inflammation is a known driver of CRC, inflammatory immune infiltrates are a positive prognostic factor in CRC and predispose to response to immune checkpoint blockade (ICB) therapy. Unfortunately, over 85% of CRC cases are primarily unresponsive to ICB due to the absence of an immune infiltrate, and even the cases that show an initial immune infiltration can become refractory to ICB. The identification of therapy supportive immune responses in the field has been partially hindered by the sparsity of suitable mouse models to recapitulate the human disease. In this study, we aimed to understand how the dysregulation of the complement anaphylatoxin C3a receptor (C3aR), observed in subsets of patients with CRC, affects the immune responses, the development of CRC, and response to ICB therapy.Methods We use a comprehensive approach encompassing analysis of publicly available human CRC datasets, inflammation-driven and newly generated spontaneous mouse models of CRC, and multiplatform high-dimensional analysis of immune responses using microbiota sequencing, RNA sequencing, and mass cytometry.Results We found that patients’ regulation of the complement C3aR is associated with epigenetic modifications. Specifically, downregulation of C3ar1 in human CRC promotes a tumor microenvironment characterized by the accumulation of innate and adaptive immune cells that support antitumor immunity. In addition, in vivo studies in our newly generated mouse model revealed that the lack of C3a in the colon activates a microbiota-mediated proinflammatory program which promotes the development of tumors with an immune signature that renders them responsive to the ICB therapy.Conclusions Our findings reveal that C3aR may act as a previously unrecognized checkpoint to enhance antitumor immunity in CRC. C3aR can thus be exploited to overcome ICB resistance in a larger group of patients with CRC.
- Published
- 2022
- Full Text
- View/download PDF
13. A robust multiplex immunofluorescence and digital pathology workflow for the characterisation of the tumour immune microenvironment
- Author
-
Amélie Viratham Pulsawatdi, Stephanie G. Craig, Victoria Bingham, Kris McCombe, Matthew P. Humphries, Seedevi Senevirathne, Susan D. Richman, Phil Quirke, Leticia Campo, Enric Domingo, Timothy S. Maughan, Jacqueline A. James, and Manuel Salto‐Tellez
- Subjects
image analysis ,multiplex immunofluorescence ,opal methodology ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Multiplex immunofluorescence is a powerful tool for the simultaneous detection of tissue‐based biomarkers, revolutionising traditional immunohistochemistry. The Opal methodology allows up to eight biomarkers to be measured concomitantly without cross‐reactivity, permitting identification of different cell populations within the tumour microenvironment. In this study, we aimed to validate a multiplex immunofluorescence workflow in two complementary multiplex panels and evaluate the tumour immune microenvironment in colorectal cancer (CRC) formalin‐fixed paraffin‐embedded tissue. We stained CRC and tonsil samples using Opal multiplex immunofluorescence on a Leica BOND RX immunostainer. We then acquired images on an Akoya Vectra Polaris and performed multispectral unmixing using inform. Antibody panels were validated on tissue microarray sections containing cores from six normal tissue types, using qupath for image analysis. Comparisons between chromogenic immunohistochemistry and multiplex immunofluorescence on consecutive sections from the same tissue microarray showed significant correlation (rs > 0.9, P‐value
- Published
- 2020
- Full Text
- View/download PDF
14. TEX264 coordinates p97- and SPRTN-mediated resolution of topoisomerase 1-DNA adducts
- Author
-
John Fielden, Katherine Wiseman, Ignacio Torrecilla, Shudong Li, Samuel Hume, Shih-Chieh Chiang, Annamaria Ruggiano, Abhay Narayan Singh, Raimundo Freire, Sylvana Hassanieh, Enric Domingo, Iolanda Vendrell, Roman Fischer, Benedikt M. Kessler, Timothy S. Maughan, Sherif F. El-Khamisy, and Kristijan Ramadan
- Subjects
Science - Abstract
Eukaryotic topoisomerase 1 (TOP1) regulates DNA topology to ensure efficient DNA replication and transcription. Here, the authors reveal insights into the molecular resolution of topoisomerase 1-DNA adducts by TEX264, p97 and SPRTN.
- Published
- 2020
- Full Text
- View/download PDF
15. Pulmonary Arterial Remodeling Is Related to the Risk Stratification and Right Ventricular-Pulmonary Arterial Coupling in Patients With Pulmonary Arterial Hypertension
- Author
-
Juan C. Grignola, Enric Domingo, Manuel López-Meseguer, Pedro Trujillo, Carlos Bravo, Santiago Pérez-Hoyos, and Antonio Roman
- Subjects
pulmonary arterial stiffness ,right ventricular-arterial coupling ,pulmonary arterial hypertension ,intravascular ultrasound ,risk stratification ,Physiology ,QP1-981 - Abstract
BackgroundPulmonary arterial (PA) stiffness has an essential contribution to the right ventricular (RV) failure pathogenesis. A comprehensive and multiparameter risk assessment allows predicting mortality and guiding treatment decisions in PA hypertension (PAH). We characterize PA remodeling with intravascular ultrasound (IVUS) in prevalent and stable patients with PAH according to the ESC/ERS risk table and analyze the RV-PA coupling consequences.MethodsTen control subjects and 20 prevalent PAH adult patients underwent right heart catheterization (RHC) with simultaneous IVUS study. We estimated cardiac index (CI), pulmonary vascular resistance, and compliance (PVR, PAC) by standard formulas. From IVUS and RHC data, PA diameter, wall thickness/luminal diameter ratio, and indexes of stiffness (pulsatility, compliance, distensibility, incremental elastic modulus - Einc-, and the stiffness index β) were measured. We evaluated RV-PA coupling by the ratio of tricuspid annular plane systolic excursion to systolic pulmonary arterial pressure (TAPSE/sPAP). The individual average risk was calculated by assigning a score of 1 (low-risk -LR-), 2 (intermediate-risk -IR-), and 3 (high-risk -HR-) for each of seven variables (functional class, six-minute walking test, brain natriuretic peptide, right atrial area and pressure, CI, and PA oxygen saturation) and rounding the average value to the nearest integer.ResultsAll PA segments interrogated showed increased vessel diameter, wall cross-sectional area (WCSA), and stiffness in patients with PAH compared to control subjects. 45% corresponded to LR, and 55% corresponded to IR PAH patients. The different measurements of PA stiffness showed significant correlations with TAPSE/sPAP (r = 0.6 to 0.76) in PAH patients. The IR group had higher PA stiffness and lower relative WCSA than LR patients (P < 0.05), and it is associated with a lower PAC and TAPSE/sPAP (P < 0.05).ConclusionIn prevalent PAH patients, the severity of proximal PA remodeling is related to the risk stratification and associated with PAC and RV-PA coupling impairment beyond the indirect effect of the mean PA pressure. The concomitant assessment of IVUS and hemodynamic parameters at diagnosis and follow-up of PAH patients could be a feasible and safe tool for risk stratification and treatment response of the PA vasculopathy during serial hemodynamic measurements.
- Published
- 2021
- Full Text
- View/download PDF
16. Robust RNA-based in situ mutation detection delineates colorectal cancer subclonal evolution
- Author
-
Ann-Marie Baker, Weini Huang, Xiao-Ming Mindy Wang, Marnix Jansen, Xiao-Jun Ma, Jeffrey Kim, Courtney M. Anderson, Xingyong Wu, Liuliu Pan, Nan Su, Yuling Luo, Enric Domingo, Timon Heide, Andrea Sottoriva, Annabelle Lewis, Andrew D. Beggs, Nicholas A. Wright, Manuel Rodriguez-Justo, Emily Park, Ian Tomlinson, and Trevor A. Graham
- Subjects
Science - Abstract
Methods that analyze intra-tumor genetic heterogeneity often do not preserve the spatial context of tumor subclones. Here, the authors present BaseScope, a mutation-specific RNA in situ hybridization assay and spatially map colorectal cancer and adenoma KRAS, BRAF and PIK3CA driver gene mutant subclones.
- Published
- 2017
- Full Text
- View/download PDF
17. Pharmacoproteomic characterisation of human colon and rectal cancer
- Author
-
Martin Frejno, Riccardo Zenezini Chiozzi, Mathias Wilhelm, Heiner Koch, Runsheng Zheng, Susan Klaeger, Benjamin Ruprecht, Chen Meng, Karl Kramer, Anna Jarzab, Stephanie Heinzlmeir, Elaine Johnstone, Enric Domingo, David Kerr, Moritz Jesinghaus, Julia Slotta‐Huspenina, Wilko Weichert, Stefan Knapp, Stephan M Feller, and Bernhard Kuster
- Subjects
CPTAC ,CRC65 ,drug response ,patient stratification ,proteomics ,Biology (General) ,QH301-705.5 ,Medicine (General) ,R5-920 - Abstract
Abstract Most molecular cancer therapies act on protein targets but data on the proteome status of patients and cellular models for proteome‐guided pre‐clinical drug sensitivity studies are only beginning to emerge. Here, we profiled the proteomes of 65 colorectal cancer (CRC) cell lines to a depth of > 10,000 proteins using mass spectrometry. Integration with proteomes of 90 CRC patients and matched transcriptomics data defined integrated CRC subtypes, highlighting cell lines representative of each tumour subtype. Modelling the responses of 52 CRC cell lines to 577 drugs as a function of proteome profiles enabled predicting drug sensitivity for cell lines and patients. Among many novel associations, MERTK was identified as a predictive marker for resistance towards MEK1/2 inhibitors and immunohistochemistry of 1,074 CRC tumours confirmed MERTK as a prognostic survival marker. We provide the proteomic and pharmacological data as a resource to the community to, for example, facilitate the design of innovative prospective clinical trials.
- Published
- 2017
- Full Text
- View/download PDF
18. Conceptos básicos en circulación pulmonar
- Author
-
Juan C. Grignola and Enric Domingo
- Subjects
Circulación ,Hemodinamia ,Arterias ,Pulmón ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Introducción: la circulación pulmonar normal del adulto es un sistema de baja resistencia y alta capacitancia. Conocer su anatomía y fisiología es importante para comprender los efectos de la enfermedad vascular pulmonar sobre la situación funcional y pronóstico en la hipertensión pulmonar. Objetivo: analizar las características anátomo-funcionales de la circulación pulmonar y sus cambios con la edad y respuesta al ejercicio. Caracterizar la rigidez arterial pulmonar y su relación con la poscarga. Metodología: se hizo una revisión narrativa de la información disponible. Conclusiones: la circulación pulmonar presenta un doble origen: las arterias pulmonares de ‘conducción’ extraparenquimatosas y las arterias pulmonares de ‘resistencia’ intrapulmonares. La poscarga arterial pulmonar puede estimarse mediante la resistencia vascular (componente estacionario) y la complacencia arterial (componente pulsátil) cuya relación es inversa y su producto caracteriza la constante de tiempo. La rigidez arterial pulmonar constituye un factor para gobernar la poscarga dinámica, y su aumento constituye un hecho temprano en el desarrollo de hipertensión pulmonar. La respuesta de la circulación pulmonar al ejercicio tiene un rol importante en el diagnóstico subclínico de la hipertensión pulmonar.
- Published
- 2017
- Full Text
- View/download PDF
19. High sensitivity and negative predictive value of the DETECT algorithm for an early diagnosis of pulmonary arterial hypertension in systemic sclerosis: application in a single center
- Author
-
Alfredo Guillén-Del Castillo, Eduardo L. Callejas-Moraga, Gabriela García, José F. Rodríguez-Palomares, Antonio Román, Cristina Berastegui, Manuel López-Meseguer, Enric Domingo, Vicente Fonollosa-Plá, and Carmen Pilar Simeón-Aznar
- Subjects
Systemic sclerosis ,Pulmonary arterial hypertension ,Echocardiography ,Screening tools ,Diseases of the musculoskeletal system ,RC925-935 - Abstract
Abstract Background Pulmonary arterial hypertension (PAH) is one of the most relevant causes of death in systemic sclerosis. The aims of this study were to analyse the recently published DETECT algorithm comparing it with European Society of Cardiology/European Respiratory Society (ESC/ERS) 2009 guidelines: as screening of PAH; (2) identifying median pulmonary arterial pressure (mPAP) ≥21 mmHg; and (3) determining any group of pulmonary hypertension (PH). Methods Eighty-three patients fulfilling LeRoy’s systemic sclerosis diagnostic criteria with at least right heart catheterization were studied retrospectively. Clinical data, serological biomarkers, echocardiographic and hemodynamic features were collected. SPSS 20.0 was used for statistical analysis. Results According to right heart catheterization findings, 35 patients with PAH and 28 with no PH met the standards for DETECT algorithm analysis: 27.0% of patients presented with functional class III/IV. Applying DETECT, the sensitivity was 100%, specificity 42.9%, the positive predictive value 68.6% and the negative predictive value 100%, whereas employing the ESC/ERS guidelines these were 91.4%, 85.7%, 88.9% and 89.3%, respectively. There were no missed diagnoses of PAH using DETECT compared with three patients missed (8.5%) using ESC/ERS guidelines. The DETECT algorithm also showed greater sensitivity and negative predictive value to identify patients with mPAP ≥21 mmHg or with any type of PH. Conclusions The DETECT algorithm is confirmed as an excellent screening method due to its high sensitivity and negative predictive value, minimizing missed diagnosis of PAH. DETECT would be accurate either for early diagnosis of borderline mPAP or any group of PH.
- Published
- 2017
- Full Text
- View/download PDF
20. Multilevel genomics of colorectal cancers with microsatellite instability—clinical impact of JAK1 mutations and consensus molecular subtype 1
- Author
-
Anita Sveen, Bjarne Johannessen, Torstein Tengs, Stine A. Danielsen, Ina A. Eilertsen, Guro E. Lind, Kaja C. G. Berg, Edward Leithe, Leonardo A. Meza-Zepeda, Enric Domingo, Ola Myklebost, David Kerr, Ian Tomlinson, Arild Nesbakken, Rolf I. Skotheim, and Ragnhild A. Lothe
- Subjects
Colorectal cancer ,Consensus molecular subtypes ,Immunogenicity ,Immunotherapy resistance ,JAK1 ,Microsatellite instability ,Medicine ,Genetics ,QH426-470 - Abstract
Abstract Background Approximately 15% of primary colorectal cancers have DNA mismatch repair deficiency, causing a complex genome with thousands of small mutations—the microsatellite instability (MSI) phenotype. We investigated molecular heterogeneity and tumor immunogenicity in relation to clinical endpoints within this distinct subtype of colorectal cancers. Methods A total of 333 primary MSI+ colorectal tumors from multiple cohorts were analyzed by multilevel genomics and computational modeling—including mutation profiling, clonality modeling, and neoantigen prediction in a subset of the tumors, as well as gene expression profiling for consensus molecular subtypes (CMS) and immune cell infiltration. Results Novel, frequent frameshift mutations in four cancer-critical genes were identified by deep exome sequencing, including in CRTC1, BCL9, JAK1, and PTCH1. JAK1 loss-of-function mutations were validated with an overall frequency of 20% in Norwegian and British patients, and mutated tumors had up-regulation of transcriptional signatures associated with resistance to anti-PD-1 treatment. Clonality analyses revealed a high level of intra-tumor heterogeneity; however, this was not associated with disease progression. Among the MSI+ tumors, the total mutation load correlated with the number of predicted neoantigens (P = 4 × 10−5), but not with immune cell infiltration—this was dependent on the CMS class; MSI+ tumors in CMS1 were highly immunogenic compared to MSI+ tumors in CMS2-4. Both JAK1 mutations and CMS1 were favorable prognostic factors (hazard ratios 0.2 [0.05–0.9] and 0.4 [0.2–0.9], respectively, P = 0.03 and 0.02). Conclusions Multilevel genomic analyses of MSI+ colorectal cancer revealed molecular heterogeneity with clinical relevance, including tumor immunogenicity and a favorable patient outcome associated with JAK1 mutations and the transcriptomic subgroup CMS1, emphasizing the potential for prognostic stratification of this clinically important subtype. See related research highlight by Samstein and Chan 10.1186/s13073-017-0438-9
- Published
- 2017
- Full Text
- View/download PDF
21. Pulmonary arterial wall disease in COPD and interstitial lung diseases candidates for lung transplantation
- Author
-
Enric Domingo, Juan C. Grignola, Rio Aguilar, Manuel López Messeguer, and Antonio Roman
- Subjects
Pulmonary hypertension ,Lung transplantation ,Pulmonary arterial wall ,Chronic obstructive pulmonary disease ,Interstitial lung disease ,Diseases of the respiratory system ,RC705-779 - Abstract
Abstract Background Pulmonary hypertension (PH) associated with lung disease has the worst prognosis of all types of PH. Pulmonary arterial vasculopathy is an early event in the natural history of chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD). The present study characterized the alterations in the structure and function of the pulmonary arterial (PA) wall of COPD and ILD candidates for lung transplantation (LTx). Methods A cohort of 73 patients, 63 pre-LTx (30 COPD, 33 ILD), and ten controls underwent simultaneous right heart catheterisation and intravascular ultrasound (IVUS). Total pulmonary resistance (TPR), capacitance (Cp), and the TPR-Cp relationship were assessed. PA stiffness and the relative area of wall thickness were estimated as pulse PA pressure/IVUS pulsatility and as [(external sectional area-intimal area)/external sectional area] × 100, respectively. Results Twenty-seven percent of patients had pulmonary arterial wedge pressure > 15 mmHg and were not analyzed. PA stiffness and the area of wall thickness were increased in comparison with controls, even in patients without PH (p
- Published
- 2017
- Full Text
- View/download PDF
22. Accounting for intensity variation in image analysis of large-scale multiplexed clinical trial datasets
- Author
-
Anja Laura Frei, Anthony McGuigan, Ritik RAK Sinha, Mark A Glaire, Faiz Jabbar, Luciana Gneo, Tijana Tomasevic, Andrea Harkin, Tim Iveson, Mark Saunders, Karin Oien, Noori Maka, Francesco Pezzella, Leticia Campo, Jennifer Hay, Joanne Edwards, Owen Sansom, Caroline Kelly, Ian Tomlinson, Wanja Kildal, Rachel Kerr, David Kerr, Havard Emil Danielsen, Enric Domingo, David N Church, and Viktor Hendrik Koelzer
- Abstract
Background: Tumour immunoprofiling captures tumour-microenvironment interactions and enables precision medicine. Multiplex immunofluorescence (mIF) imaging can provide comprehensive quantitative and spatial information for multiple immune markers. However, application at scale to clinical trial samples sourced from multiple institutions is challenging due to pre-analytical heterogeneity. Methods: We analysed 12'592 tissue microarray (TMA) spots from 3'545 colorectal cancers (CRC) sourced from more than 240 institutions in two clinical trials (QUASAR 2 and SCOT) stained for CD4, CD8, CD20, CD68, FoxP3, pan-cytokeratin and DAPI by mIF. TMA cores were multi-spectrally imaged by digital pathology and analysed by cell-based and pixel-based marker analysis. We developed and validated an adaptive thresholding method to account for inter- and intra-slide intensity variation in TMA analysis, compared the numerical results between analysis approaches and validated against the current gold standard of single-plex chromogenic immunohistochemistry (IHC). Results: Adaptive thresholding at a slide and spot level effectively ameliorated inter- and intra-slide intensity variation enabling high-throughput analysis of mIF-stained TMA cores by digital pathology and improving the image analysis results compared to methods using a single global threshold. Comparison of our mIF approach with CD8 IHC data derived from subsequent sections indicates the validity of our method (Spearman's rank correlation coefficients (SCC) between 0.63 and 0.66, p-value << 0.01). Evaluation of correlation between cell-based and pixel-based analysis results confirms equivalency (SCC > 0.8, p<< 0.01, except for CD20 in epithelium region) of both analytical approaches for precision immunoprofiling by mIF. Conclusions: This study reports an analytical approach to the largest multiparameter immunoprofiling study of clinical trial samples to date and establishes an adaptive thresholding method to account for inter- and intra-slide variation introduced by pre-analytical heterogeneity. This approach can enable the application of mIF immunoprofiling of clinical trial TMA datasets at scale.
- Published
- 2023
- Full Text
- View/download PDF
23. Ultra-Low DNA Input into Whole Genome Methylation Assays and Detection of Oncogenic Methylation and Copy Number Variants in Circulating Tumour DNA
- Author
-
Celina Whalley, Karl Payne, Enric Domingo, Andrew Blake, Susan Richman, Jill Brooks, Nikolaos Batis, Rachel Spruce, S-CORT Consortium, Hisham Mehanna, Paul Nankivell, and Andrew D. Beggs
- Subjects
circulating tumour DNA ,formalin fixed paraffin embedded ,epigenome ,Genetics ,QH426-470 ,Biotechnology ,TP248.13-248.65 - Abstract
Background: Abnormal CpG methylation in cancer is ubiquitous and generally detected in tumour specimens using a variety of techniques at a resolution encompassing single CpG loci to genome wide coverage. Analysis of samples with very low DNA inputs, such as formalin fixed (FFPE) biopsy specimens from clinical trials or circulating tumour DNA is challenging at the genome-wide level because of lack of available input. We present the results of low input experiments into the Illumina Infinium HD methylation assay on FFPE specimens and ctDNA samples. Methods: For all experiments, the Infinium HD assay for methylation was used. In total, forty-eight FFPE specimens were used at varying concentrations (lowest input 50 ng); eighteen blood derived specimens (lowest input 10 ng) and six matched ctDNA input (lowest input 10 ng)/fresh tumour specimens (lowest input 250 ng) were processed. Downstream analysis was performed in R/Bioconductor for quality control metrics and differential methylation analysis as well as copy number calls. Results: Correlation coefficients for CpG methylation were high at the probe level averaged R2 = 0.99 for blood derived samples and R2 > 0.96 for the FFPE samples. When matched ctDNA/fresh tumour samples were compared, R2 > 0.91 between the two. Results of differential methylation analysis did not vary significantly by DNA input in either the blood or FFPE groups. There were differences seen in the ctDNA group as compared to their paired tumour sample, possibly because of enrichment for tumour material without contaminating normal. Copy number variants observed in the tumour were generally also seen in the paired ctDNA sample with good concordance via DQ plot. Conclusions: The Illumina Infinium HD methylation assay can robustly detect methylation across a range of sample types, including ctDNA, down to an input of 10 ng. It can also reliably detect oncogenic methylation changes and copy number variants in ctDNA. These findings demonstrate that these samples can now be accessed by methylation array technology, allowing analysis of these important sample types.
- Published
- 2021
- Full Text
- View/download PDF
24. Data from In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer
- Author
-
Philip D. Dunne, Louise C. Brown, Timothy S. Maughan, Mark Lawler, Daniel B. Longley, Richard S. Kaplan, Letitia Campo, Viktor H. Koelzer, Ian Tomlinson, Patrick G. Johnston, Richard D. Kennedy, Manuel Salto-Tellez, Nicholas P. West, Philip Quirke, Dion G. Morton, Matthew T. Seymour, Ultan McDermott, Stephanie G. Craig, Matthew P. Humphries, Raheleh Amirkhah, Aikaterina Chatzipli, Gemma E. Logan, Steven M. Walker, Michael Youdell, Susan D. Richman, Keara L. Redmond, Sylvana Hassanieh, Andrew Blake, Enric Domingo, David J. Fisher, and Sudhir B. Malla
- Abstract
Purpose:The DNA damage immune response (DDIR) assay was developed in breast cancer based on biology associated with deficiencies in homologous recombination and Fanconi anemia pathways. A positive DDIR call identifies patients likely to respond to platinum-based chemotherapies in breast and esophageal cancers. In colorectal cancer, there is currently no biomarker to predict response to oxaliplatin. We tested the ability of the DDIR assay to predict response to oxaliplatin-based chemotherapy in colorectal cancer and characterized the biology in DDIR-positive colorectal cancer.Experimental Design:Samples and clinical data were assessed according to DDIR status from patients who received either 5-fluorouracil (5-FU) or 5FUFA (bolus and infusion 5-FU with folinic acid) plus oxaliplatin (FOLFOX) within the FOCUS trial (n = 361, stage IV), or neoadjuvant FOLFOX in the FOxTROT trial (n = 97, stage II/III). Whole transcriptome, mutation, and IHC data of these samples were used to interrogate the biology of DDIR in colorectal cancer.Results:Contrary to our hypothesis, DDIR-negative patients displayed a trend toward improved outcome for oxaliplatin-based chemotherapy compared with DDIR-positive patients. DDIR positivity was associated with microsatellite instability (MSI) and colorectal molecular subtype 1. Refinement of the DDIR signature, based on overlapping IFN-related chemokine signaling associated with DDIR positivity across colorectal cancer and breast cancer cohorts, further confirmed that the DDIR assay did not have predictive value for oxaliplatin-based chemotherapy in colorectal cancer.Conclusions:DDIR positivity does not predict improved response following oxaliplatin treatment in colorectal cancer. However, data presented here suggest the potential of the DDIR assay in identifying immune-rich tumors that may benefit from immune checkpoint blockade, beyond current use of MSI status.
- Published
- 2023
- Full Text
- View/download PDF
25. Data from Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response
- Author
-
Gareth L. Bond, Hannah Carter, Clare Turnbull, Ian Tomlinson, Enric Domingo, Timothy S. Maughan, Sarah P. Blagden, Meghana Pagadala, Daniel V. Ebner, Val Millar, Andrew Protheroe, Claire Palles, Lukasz F. Grochola, Rick Jansen, Chey Loveday, Paul D. Pharoah, Siddhartha Kar, Janet Shipley, Joanna L. Selfe, Anderson J. Ryan, Yanyan Jiang, Jorge Zeron-Medina, Douglas A. Bell, Xuting Wang, David Sims, Mirvat Surakhy, Sarah De Val, Svanhild Nornes, Samantha Moore, Natasha Sahgal, Elisabeth Bond, Marsha D. Wallace, Philipp H. Richter, Katherine Brown, Giovanni Stracquadanio, Lingyun Xiong, Isaac Kitchen-Smith, and Ping Zhang
- Abstract
Insights into oncogenesis derived from cancer susceptibility loci (SNP) hold the potential to facilitate better cancer management and treatment through precision oncology. However, therapeutic insights have thus far been limited by our current lack of understanding regarding both interactions of these loci with somatic cancer driver mutations and their influence on tumorigenesis. For example, although both germline and somatic genetic variation to the p53 tumor suppressor pathway are known to promote tumorigenesis, little is known about the extent to which such variants cooperate to alter pathway activity. Here we hypothesize that cancer risk-associated germline variants interact with somatic TP53 mutational status to modify cancer risk, progression, and response to therapy. Focusing on a cancer risk SNP (rs78378222) with a well-documented ability to directly influence p53 activity as well as integration of germline datasets relating to cancer susceptibility with tumor data capturing somatically-acquired genetic variation provided supportive evidence for this hypothesis. Integration of germline and somatic genetic data enabled identification of a novel entry point for therapeutic manipulation of p53 activities. A cluster of cancer risk SNPs resulted in increased expression of prosurvival p53 target gene KITLG and attenuation of p53-mediated responses to genotoxic therapies, which were reversed by pharmacologic inhibition of the prosurvival c-KIT signal. Together, our results offer evidence of how cancer susceptibility SNPs can interact with cancer driver genes to affect cancer progression and identify novel combinatorial therapies.Significance:These results offer evidence of how cancer susceptibility SNPs can interact with cancer driver genes to affect cancer progression and present novel therapeutic targets.
- Published
- 2023
- Full Text
- View/download PDF
26. Supplementary Data from Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response
- Author
-
Gareth L. Bond, Hannah Carter, Clare Turnbull, Ian Tomlinson, Enric Domingo, Timothy S. Maughan, Sarah P. Blagden, Meghana Pagadala, Daniel V. Ebner, Val Millar, Andrew Protheroe, Claire Palles, Lukasz F. Grochola, Rick Jansen, Chey Loveday, Paul D. Pharoah, Siddhartha Kar, Janet Shipley, Joanna L. Selfe, Anderson J. Ryan, Yanyan Jiang, Jorge Zeron-Medina, Douglas A. Bell, Xuting Wang, David Sims, Mirvat Surakhy, Sarah De Val, Svanhild Nornes, Samantha Moore, Natasha Sahgal, Elisabeth Bond, Marsha D. Wallace, Philipp H. Richter, Katherine Brown, Giovanni Stracquadanio, Lingyun Xiong, Isaac Kitchen-Smith, and Ping Zhang
- Abstract
Supplementary Methods; Supplementary Figures S1-S5
- Published
- 2023
- Full Text
- View/download PDF
27. Supplementary Results from In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer
- Author
-
Philip D. Dunne, Louise C. Brown, Timothy S. Maughan, Mark Lawler, Daniel B. Longley, Richard S. Kaplan, Letitia Campo, Viktor H. Koelzer, Ian Tomlinson, Patrick G. Johnston, Richard D. Kennedy, Manuel Salto-Tellez, Nicholas P. West, Philip Quirke, Dion G. Morton, Matthew T. Seymour, Ultan McDermott, Stephanie G. Craig, Matthew P. Humphries, Raheleh Amirkhah, Aikaterina Chatzipli, Gemma E. Logan, Steven M. Walker, Michael Youdell, Susan D. Richman, Keara L. Redmond, Sylvana Hassanieh, Andrew Blake, Enric Domingo, David J. Fisher, and Sudhir B. Malla
- Abstract
Supplementary Results
- Published
- 2023
- Full Text
- View/download PDF
28. Supplementary Figure from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
- Author
-
Philip D. Dunne, Nigel B. Jamieson, Viktor H. Koelzer, Felicity Lamrock, Owen J. Sansom, Mark Lawler, Tim Maughan, Simon Leedham, Maurice B. Loughrey, James Jackson, Enric Domingo, Svetlana Sakhnevych, Keara L. Redmond, Emily Rogan, Aoife J. McCooey, Raheleh Amirkhah, Sudhir B. Malla, Shania M. Corry, Baharak Ahmaderaghi, Andrew J. Cameron, Assya Legrini, Colin Wood, Holly Leslie, Ryan M. Byrne, and Natalie C. Fisher
- Abstract
Supplementary Figure from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
- Published
- 2023
- Full Text
- View/download PDF
29. Data from KRAS Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer
- Author
-
Oliver M. Sieber, David Kerr, Rachel Midgley, Ian P.M. Tomlinson, Enric Domingo, Robert L. Strausberg, Dana Busam, Qi Zhao, Paul McMurrick, Adrian Polglase, Roger Berry, Peter W.G. Carne, Simon Knight, Adrian W. Pick, Peter M. Evans, Valery Usatoff, Benjamin N.J. Thomson, Katharine J. Drummond, Michael Christie, Robert N. Jorissen, Peter Gibbs, Jayesh Desai, Lara Lipton, and Jeanne Tie
- Abstract
Purpose: Oncogene mutations contribute to colorectal cancer development. We searched for differences in oncogene mutation profiles between colorectal cancer metastases from different sites and evaluated these as markers for site of relapse.Experimental Design: One hundred colorectal cancer metastases were screened for mutations in 19 oncogenes, and further 61 metastases and 87 matched primary cancers were analyzed for genes with identified mutations. Mutation prevalence was compared between (a) metastases from liver (n = 65), lung (n = 50), and brain (n = 46), (b) metastases and matched primary cancers, and (c) metastases and an independent cohort of primary cancers (n = 604). Mutations differing between metastasis sites were evaluated as markers for site of relapse in 859 patients from the VICTOR trial.Results: In colorectal cancer metastases, mutations were detected in 4 of 19 oncogenes: BRAF (3.1%), KRAS (48.4%), NRAS (6.2%), and PIK3CA (16.1%). KRAS mutation prevalence was significantly higher in lung (62.0%) and brain (56.5%) than in liver metastases (32.3%; P = 0.003). Mutation status was highly concordant between primary cancer and metastasis from the same individual. Compared with independent primary cancers, KRAS mutations were more common in lung and brain metastases (P < 0.005), but similar in liver metastases. Correspondingly, KRAS mutation was associated with lung relapse (HR = 2.1; 95% CI, 1.2 to 3.5, P = 0.007) but not liver relapse in patients from the VICTOR trial.Conclusions: KRAS mutation seems to be associated with metastasis in specific sites, lung and brain, in colorectal cancer patients. Our data highlight the potential of somatic mutations for informing surveillance strategies. Clin Cancer Res; 17(5); 1122–30. ©2011 AACR.
- Published
- 2023
- Full Text
- View/download PDF
30. Supplementary Data from The Interleukin 22 Pathway Interacts with Mutant KRAS to Promote Poor Prognosis in Colon Cancer
- Author
-
Fiona Powrie, Nathaniel R. West, Timothy S. Maughan, Sabine Tejpar, Mauro Delorenzi, Viktor Hendrik Koelzer, Enric Domingo, Lucy C. Garner, Alina Janney, Samuel J. Bullers, Matthias Friedrich, Elizabeth H. Mann, David Barras, and Sarah McCuaig
- Abstract
Supplementary data to accompany manuscript
- Published
- 2023
- Full Text
- View/download PDF
31. Data from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
- Author
-
Philip D. Dunne, Nigel B. Jamieson, Viktor H. Koelzer, Felicity Lamrock, Owen J. Sansom, Mark Lawler, Tim Maughan, Simon Leedham, Maurice B. Loughrey, James Jackson, Enric Domingo, Svetlana Sakhnevych, Keara L. Redmond, Emily Rogan, Aoife J. McCooey, Raheleh Amirkhah, Sudhir B. Malla, Shania M. Corry, Baharak Ahmaderaghi, Andrew J. Cameron, Assya Legrini, Colin Wood, Holly Leslie, Ryan M. Byrne, and Natalie C. Fisher
- Abstract
Purpose:Precise mechanism-based gene expression signatures (GES) have been developed in appropriate in vitro and in vivo model systems, to identify important cancer-related signaling processes. However, some GESs originally developed to represent specific disease processes, primarily with an epithelial cell focus, are being applied to heterogeneous tumor samples where the expression of the genes in the signature may no longer be epithelial-specific. Therefore, unknowingly, even small changes in tumor stroma percentage can directly influence GESs, undermining the intended mechanistic signaling.Experimental Design:Using colorectal cancer as an exemplar, we deployed numerous orthogonal profiling methodologies, including laser capture microdissection, flow cytometry, bulk and multiregional biopsy clinical samples, single-cell RNA sequencing and finally spatial transcriptomics, to perform a comprehensive assessment of the potential for the most widely used GESs to be influenced, or confounded, by stromal content in tumor tissue. To complement this work, we generated a freely-available resource, ConfoundR; https://confoundr.qub.ac.uk/, that enables users to test the extent of stromal influence on an unlimited number of the genes/signatures simultaneously across colorectal, breast, pancreatic, ovarian and prostate cancer datasets.Results:Findings presented here demonstrate the clear potential for misinterpretation of the meaning of GESs, due to widespread stromal influences, which in-turn can undermine faithful alignment between clinical samples and preclinical data/models, particularly cell lines and organoids, or tumor models not fully recapitulating the stromal and immune microenvironment.Conclusions:Efforts to faithfully align preclinical models of disease using phenotypically-designed GESs must ensure that the signatures themselves remain representative of the same biology when applied to clinical samples.
- Published
- 2023
- Full Text
- View/download PDF
32. Supplementary Data from KRAS Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer
- Author
-
Oliver M. Sieber, David Kerr, Rachel Midgley, Ian P.M. Tomlinson, Enric Domingo, Robert L. Strausberg, Dana Busam, Qi Zhao, Paul McMurrick, Adrian Polglase, Roger Berry, Peter W.G. Carne, Simon Knight, Adrian W. Pick, Peter M. Evans, Valery Usatoff, Benjamin N.J. Thomson, Katharine J. Drummond, Michael Christie, Robert N. Jorissen, Peter Gibbs, Jayesh Desai, Lara Lipton, and Jeanne Tie
- Abstract
Supplementary Tables S1-S4.
- Published
- 2023
- Full Text
- View/download PDF
33. supplementary figures, from In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer
- Author
-
Philip D. Dunne, Louise C. Brown, Timothy S. Maughan, Mark Lawler, Daniel B. Longley, Richard S. Kaplan, Letitia Campo, Viktor H. Koelzer, Ian Tomlinson, Patrick G. Johnston, Richard D. Kennedy, Manuel Salto-Tellez, Nicholas P. West, Philip Quirke, Dion G. Morton, Matthew T. Seymour, Ultan McDermott, Stephanie G. Craig, Matthew P. Humphries, Raheleh Amirkhah, Aikaterina Chatzipli, Gemma E. Logan, Steven M. Walker, Michael Youdell, Susan D. Richman, Keara L. Redmond, Sylvana Hassanieh, Andrew Blake, Enric Domingo, David J. Fisher, and Sudhir B. Malla
- Abstract
Figures S1-S9, Tables S1, S2
- Published
- 2023
- Full Text
- View/download PDF
34. Supplementary Table from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
- Author
-
Philip D. Dunne, Nigel B. Jamieson, Viktor H. Koelzer, Felicity Lamrock, Owen J. Sansom, Mark Lawler, Tim Maughan, Simon Leedham, Maurice B. Loughrey, James Jackson, Enric Domingo, Svetlana Sakhnevych, Keara L. Redmond, Emily Rogan, Aoife J. McCooey, Raheleh Amirkhah, Sudhir B. Malla, Shania M. Corry, Baharak Ahmaderaghi, Andrew J. Cameron, Assya Legrini, Colin Wood, Holly Leslie, Ryan M. Byrne, and Natalie C. Fisher
- Abstract
Supplementary Table from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
- Published
- 2023
- Full Text
- View/download PDF
35. Data from The Interleukin 22 Pathway Interacts with Mutant KRAS to Promote Poor Prognosis in Colon Cancer
- Author
-
Fiona Powrie, Nathaniel R. West, Timothy S. Maughan, Sabine Tejpar, Mauro Delorenzi, Viktor Hendrik Koelzer, Enric Domingo, Lucy C. Garner, Alina Janney, Samuel J. Bullers, Matthias Friedrich, Elizabeth H. Mann, David Barras, and Sarah McCuaig
- Abstract
Purpose:The cytokine IL22 promotes tumor progression in murine models of colorectal cancer. However, the clinical significance of IL22 in human colorectal cancer remains unclear. We sought to determine whether the IL22 pathway is associated with prognosis in human colorectal cancer, and to identify mechanisms by which IL22 can influence disease progression.Experimental Design:Transcriptomic data from stage II/III colon cancers in independent discovery (GSE39582 population-based cohort, N = 566) and verification (PETACC3 clinical trial, N = 752) datasets were used to investigate the association between IL22 receptor expression (encoded by the genes IL22RA1 and IL10RB), tumor mutation status, and clinical outcome using Cox proportional hazard models. Functional interactions between IL22 and mutant KRAS were elucidated using human colorectal cancer cell lines and primary tumor organoids.Results:Transcriptomic analysis revealed a poor-prognosis subset of tumors characterized by high expression of IL22RA1, the alpha subunit of the heterodimeric IL22 receptor, and KRAS mutation [relapse-free survival (RFS): HR = 2.93, P = 0.0006; overall survival (OS): HR = 2.45, P = 0.0023]. KRAS mutations showed a similar interaction with IL10RB and conferred the worst prognosis in tumors with high expression of both IL22RA1 and IL10RB (RFS: HR = 3.81, P = 0.0036; OS: HR = 3.90, P = 0.0050). Analysis of human colorectal cancer cell lines and primary tumor organoids, including an isogenic cell line pair that differed only in KRAS mutation status, showed that IL22 and mutant KRAS cooperatively enhance cancer cell proliferation, in part through augmentation of the Myc pathway.Conclusions:Interactions between KRAS and IL22 signaling may underlie a previously unrecognized subset of clinically aggressive colorectal cancer that could benefit from therapeutic modulation of the IL22 pathway.
- Published
- 2023
- Full Text
- View/download PDF
36. Supplementary Data from In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer
- Author
-
Philip D. Dunne, Louise C. Brown, Timothy S. Maughan, Mark Lawler, Daniel B. Longley, Richard S. Kaplan, Letitia Campo, Viktor H. Koelzer, Ian Tomlinson, Patrick G. Johnston, Richard D. Kennedy, Manuel Salto-Tellez, Nicholas P. West, Philip Quirke, Dion G. Morton, Matthew T. Seymour, Ultan McDermott, Stephanie G. Craig, Matthew P. Humphries, Raheleh Amirkhah, Aikaterina Chatzipli, Gemma E. Logan, Steven M. Walker, Michael Youdell, Susan D. Richman, Keara L. Redmond, Sylvana Hassanieh, Andrew Blake, Enric Domingo, David J. Fisher, and Sudhir B. Malla
- Abstract
supplementary methods
- Published
- 2023
- Full Text
- View/download PDF
37. Supplementary Table 1-3 from Mechanisms of Inactivation of the Receptor Tyrosine Kinase EPHB2 in Colorectal Tumors
- Author
-
Diego Arango, Simo Schwartz, Lauri A. Aaltonen, Johannes F. Gebert, John M. Mariadason, Hiroyuki Yamamoto, Kohzoh Imai, Manel Armengol, Eloi Espín, Päivi Laiho, Lars Konrad, Andrew J. Wilson, Stefan M. Woerner, Enric Domingo, Antti Kokko, Veronica Davalos, and Hafid Alazzouzi
- Abstract
Supplementary Table 1-3 from Mechanisms of Inactivation of the Receptor Tyrosine Kinase EPHB2 in Colorectal Tumors
- Published
- 2023
- Full Text
- View/download PDF
38. Data from Mechanisms of Inactivation of the Receptor Tyrosine Kinase EPHB2 in Colorectal Tumors
- Author
-
Diego Arango, Simo Schwartz, Lauri A. Aaltonen, Johannes F. Gebert, John M. Mariadason, Hiroyuki Yamamoto, Kohzoh Imai, Manel Armengol, Eloi Espín, Päivi Laiho, Lars Konrad, Andrew J. Wilson, Stefan M. Woerner, Enric Domingo, Antti Kokko, Veronica Davalos, and Hafid Alazzouzi
- Abstract
The receptor tyrosine kinase EPHB2 has recently been shown to be a direct transcriptional target of TCF/β-catenin. Premalignant lesions of the colon express high levels of EPHB2 but the expression of this kinase is reduced or lost in most colorectal carcinomas. In addition, inactivation of EPHB2 has been shown to accelerate tumorigenesis initiated by APC mutation in the colon and rectum. In this study, we investigated the molecular mechanisms responsible for the inactivation of EPHB2 in colorectal tumors. We show here the presence of mutations in repetitive sequences in exon 17 of EPHB2 in 6 of 29 adenomas with microsatellite instability (MSI), and 101 of 246 MSI carcinomas (21% and 41%, respectively). Moreover, we found EPHB2 promoter hypermethylation in 54 of the 101 colorectal tumors studied (53%). Importantly, EPHB2 expression was restored after treatment of EPHB2-methylated colon cancer cells with the DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine. In conclusion, in this study, we elucidate the molecular mechanisms of inactivation of EPHB2 and show for the first time the high incidence of frameshift mutations in MSI colorectal tumors and aberrant methylation of the regulatory sequences of this important tumor suppressor gene.
- Published
- 2023
- Full Text
- View/download PDF
39. Proximal pulmonary arterial wall disease in patients with persistent pulmonary hypertension after successful left-sided valve replacement according to the hemodynamic phenotype
- Author
-
Enric Domingo, Juan C. Grignola, Pedro Trujillo, Rio Aguilar, and Antonio Roman
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 ,Diseases of the respiratory system ,RC705-779 - Abstract
Regression of pulmonary hypertension (PH) is often incomplete after successful left-sided valve replacement (LSVR). Proximal pulmonary arterial (PPA) wall disease can be involved in patients with persistent-PH after LSVR, affecting the right ventricular to pulmonary arterial (RV-PA) coupling. Fifteen patients underwent successful LSVR at least one year ago presenting PH by echo (> 50 mmHg). Prosthesis-patient mismatch and left ventricular dysfunction were discarded. All patients underwent hemodynamic and intravascular ultrasound (IVUS) study. We estimated PPA stiffness (elastic modulus [EM]) and the relative area wall thickness (AWT). Acute vasoreactivity was assessed by inhaled nitric oxide (iNO) testing. RV-PA coupling was estimated by the tricuspid annular plane systolic excursion to systolic pulmonary arterial pressure ratio. Patients were classified as isolated post-capillary PH (Ipc-PH; pulmonary vascular resistance [PVR] ≤ 3 WU and/or diastolic pulmonary gradient [DPG] 3 WU and DPG ≥ 7 mmHg). Both Ipc-PH and Cpc-PH showed a significant increase of EM and AWT. Despite normal PVR and DPG, Ipc-PH had a significant decrease in pulmonary arterial capacitance and RV-PA coupling impairment. Cpc-PH had worse PA stiffness and RV-PA coupling to Ipc-PH ( P
- Published
- 2018
- Full Text
- View/download PDF
40. Innate immune receptor C5aR1 regulates cancer cell fate and can be targeted to improve radiotherapy in tumours with immunosuppressive microenvironments
- Author
-
Callum Beach, David MacLean, Dominika Majorova, Stavros Melemenidis, Dhanya K. Nambiar, Ryan K. Kim, Gabriel N Valbuena, Silvia Guglietta, Carsten Krieg, Damavandi Mahnaz Darvish, Tatsuya Suwa, Alistair Easton, Enric Domingo, Eui Jung Moon, Dadi Jiang, Yanyan Jiang, Albert C Koong, Trent M. Woodruff, Edward E. Graves, Tim Maughan, Simon J. A. Buczacki, Manuel Stucki, Quynh-Thu Le, Simon J. Leedham, Amato J. Giaccia, and Monica M Olcina
- Abstract
An immunosuppressive microenvironment causes poor tumour T-cell infiltration and is associated with reduced patient overall survival in colorectal cancer. How to improve treatment responses in these tumours is still a challenge. Using an integrated screening approach to identify cancer-specific vulnerabilities, we identify complement receptor C5aR1 as a druggable target which when inhibited improves radiotherapy even in tumours displaying immunosuppressive features and poor CD8+ T-cell infiltration. While C5aR1 is well-known for its role in the immune compartment, we find that C5aR1 is also robustly expressed on malignant epithelial cells, highlighting potential tumour-cell specific functions. C5aR1 targeting results in increased NF-κB-dependent apoptosis specifically in tumours and not normal tissues; indicating that in malignant cells, C5aR1 primarily regulates cell fate. Collectively, these data reveal that increased complement gene expression is part of the stress response mounted by irradiated tumours and that targeting C5aR1 can improve radiotherapy even in tumours displaying immunosuppressive features.
- Published
- 2023
- Full Text
- View/download PDF
41. The clinical features of polymerase proof-reading associated polyposis (PPAP) and recommendations for patient management
- Author
-
Laura Chegwidden, Stephen E. Kearsey, Josh McGuire, Susan K. Clark, Claire Palles, Ian Tomlinson, Enric Domingo, Ellen Heitzer, Andrew Latchford, Lynn Martin, David J. Kerr, Vicky Cuthill, and Rachel Kerr
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Colorectal cancer ,POLD1 ,Malignancy ,PPAP ,Internal medicine ,Genetics ,medicine ,Humans ,exonuclease domain mutation ,Poly-ADP-Ribose Binding Proteins ,Germ-Line Mutation ,Genetics (clinical) ,Propylamines ,business.industry ,Endometrial cancer ,Cancer ,DNA Polymerase II ,medicine.disease ,Human genetics ,Endometrial Neoplasms ,Clinical trial ,POLE ,Female ,Colorectal Neoplasms ,Ovarian cancer ,business - Abstract
Pathogenic germline exonuclease domain (ED) variants of POLE and POLD1 cause the Mendelian dominant condition polymerase proof-reading associated polyposis (PPAP). We aimed to describe the clinical features of all PPAP patients with probably pathogenic variants. We identified patients with a variants mapping to the EDs of POLE or POLD1 from cancer genetics clinics, a colorectal cancer (CRC) clinical trial, and systematic review of the literature. We used multiple evidence sources to separate ED variants into those with strong evidence of pathogenicity and those of uncertain importance. We performed quantitative analysis of the risk of CRC, colorectal adenomas, endometrial cancer or any cancer in the former group. 132 individuals carried a probably pathogenic ED variant (105 POLE, 27 POLD1). The earliest malignancy was colorectal cancer at 14. The most common tumour types were colorectal, followed by endometrial in POLD1 heterozygotes and duodenal in POLE heterozygotes. POLD1-mutant cases were at a significantly higher risk of endometrial cancer than POLE heterozygotes. Five individuals with a POLE pathogenic variant, but none with a POLD1 pathogenic variant, developed ovarian cancer. Nine patients with POLE pathogenic variants and one with a POLD1 pathogenic variant developed brain tumours. Our data provide important evidence for PPAP management. Colonoscopic surveillance is recommended from age 14 and upper-gastrointestinal surveillance from age 25. The management of other tumour risks remains uncertain, but surveillance should be considered. In the absence of strong genotype–phenotype associations, these recommendations should apply to all PPAP patients.
- Published
- 2021
- Full Text
- View/download PDF
42. Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Hypertension. Are Intravascular Ultrasound and Stents Helpful?
- Author
-
Enric Domingo
- Subjects
General Engineering - Published
- 2022
- Full Text
- View/download PDF
43. Biological misinterpretation of transcriptional signatures in tumour samples can unknowingly undermine mechanistic understanding and faithful alignment with preclinical data
- Author
-
Natalie C. Fisher, Ryan M. Byrne, Holly Leslie, Colin Wood, Assya Legrini, Andrew J. Cameron, Baharak Ahmaderaghi, Shania M. Corry, Sudhir B. Malla, Raheleh Amirkhah, Aoife J. McCooey, Emily Rogan, Keara L. Redmond, Svetlana Sakhnevych, Enric Domingo, James Jackson, Maurice B. Loughrey, Simon Leedham, Tim Maughan, Mark Lawler, Owen J. Sansom, Felicity Lamrock, Viktor H. Koelzer, Nigel B. Jamieson, Philip D. Dunne, and University of Zurich
- Subjects
Male ,Ovarian Neoplasms ,Cancer Research ,Gene Expression Profiling ,Prostatic Neoplasms ,610 Medicine & health ,Article ,Gene Expression Regulation, Neoplastic ,SDG 3 - Good Health and Well-being ,Oncology ,10049 Institute of Pathology and Molecular Pathology ,Tumor Microenvironment ,Humans ,2730 Oncology ,1306 Cancer Research ,Female ,Stromal Cells ,Transcriptome - Abstract
Purpose: Precise mechanism-based gene expression signatures (GES) have been developed in appropriate in vitro and in vivo model systems, to identify important cancer-related signaling processes. However, some GESs originally developed to represent specific disease processes, primarily with an epithelial cell focus, are being applied to heterogeneous tumor samples where the expression of the genes in the signature may no longer be epithelial-specific. Therefore, unknowingly, even small changes in tumor stroma percentage can directly influence GESs, undermining the intended mechanistic signaling. Experimental Design: Using colorectal cancer as an exemplar, we deployed numerous orthogonal profiling methodologies, including laser capture microdissection, flow cytometry, bulk and multiregional biopsy clinical samples, single-cell RNA sequencing and finally spatial transcriptomics, to perform a comprehensive assessment of the potential for the most widely used GESs to be influenced, or confounded, by stromal content in tumor tissue. To complement this work, we generated a freely-available resource, ConfoundR; https://confoundr.qub.ac.uk/, that enables users to test the extent of stromal influence on an unlimited number of the genes/signatures simultaneously across colorectal, breast, pancreatic, ovarian and prostate cancer datasets. Results: Findings presented here demonstrate the clear potential for misinterpretation of the meaning of GESs, due to widespread stromal influences, which in-turn can undermine faithful alignment between clinical samples and preclinical data/models, particularly cell lines and organoids, or tumor models not fully recapitulating the stromal and immune microenvironment. Conclusions: Efforts to faithfully align preclinical models of disease using phenotypically-designed GESs must ensure that the signatures themselves remain representative of the same biology when applied to clinical samples.
- Published
- 2022
- Full Text
- View/download PDF
44. Pulmonary hypertension due to chronic pulmonary thromboembolism. An evolving disease
- Author
-
Santiago Pérez Hoyos, Enric Domingo, and Juan C. Grignola
- Subjects
medicine.medical_specialty ,business.industry ,Hypertension, Pulmonary ,MEDLINE ,General Medicine ,Disease ,Pulmonary Artery ,medicine.disease ,Pulmonary hypertension ,Chronic pulmonary thromboembolism ,Chronic disease ,Internal medicine ,medicine.artery ,Chronic Disease ,Pulmonary artery ,medicine ,Cardiology ,Humans ,Pulmonary Embolism ,business - Published
- 2021
- Full Text
- View/download PDF
45. La hipertensión pulmonar secundaria a tromboembolia pulmonar crónica. Una enfermedad en evolución
- Author
-
Juan C. Grignola, Enric Domingo, and Santiago Pérez Hoyos
- Subjects
Gynecology ,medicine.medical_specialty ,business.industry ,medicine ,Cardiology and Cardiovascular Medicine ,business - Published
- 2021
- Full Text
- View/download PDF
46. A Machine Learning Model of Complete Response to Radiation in Rectal Cancer Reveals Immune Infiltrate and TGFβ Signalling as Key Predictors
- Author
-
Enric Domingo, Sanjay Rathee, Andrew Blake, Leslie Samuel, Graeme Murray, David Sebag-Montefiore, Simon Gollins, Nick P. West, Rubina Begum, Susan Richman, Philip Quirke, Keara Redman, Aikaterini Chatzpili, Alessandro Barberis, sylvana Hassanieh, Umair Mahmoud, Michael Youdell, ultan mcdermot, Viktor H. Koelzer, Simon Leedham, Philip Dunne, Ian Tomlinson, Francesca Buffa, Tim Maughan, and S:CORT Consortium
- Subjects
History ,Polymers and Plastics ,Business and International Management ,Industrial and Manufacturing Engineering - Published
- 2022
- Full Text
- View/download PDF
47. Can an ultrathin strut stent design and a polymer free, proendothelializing probucol matrix coating improve early strut healing? The FRIENDLY-OCT trial. An intra-patient randomized study with OCT, evaluating early strut coverage of a novel probucol coated polymer-free and ultra-thin strut sirolimus-eluting stent compared to a biodegradable polymer sirolimus-eluting stent
- Author
-
Imanol Otaegui Irurueta, Silvia González Sucarrats, Jose Luis Barrón Molina, Armando Pérez de Prado, Monica Massotti, Maria Ángeles Carmona Ramírez, Gerard Martí, Neus Bellera, Bernat Serra, Vicenç Serra, Enric Domingo, María López-Benito, Manuel Sabaté, Ignacio Ferreira González, and Bruno García del Blanco
- Subjects
Sirolimus ,Percutaneous Coronary Intervention ,Probucol ,Treatment Outcome ,Polymers ,Absorbable Implants ,Humans ,Drug-Eluting Stents ,Stents ,Cardiology and Cardiovascular Medicine ,Prosthesis Design ,Tomography, Optical Coherence - Abstract
incomplete strut coverage determines the risk of stent thrombosis in the first months after stent implantation.To evaluate the potential better early healing of a novel probucol coated polymer free ultra-thin strut sirolimus eluting stent (PF-SES). [Clinical trial unique identifier: NCT02785237].Patients with two (angiographically similar) lesions with clinical indication for PCI were enrolled. The investigated stent was compared to a thin strut, bioresorbable polymer, sirolimus eluting stent (BP-SES). Every patient received both stents, one in each lesion, assigned in a randomized sequence. OCT was systematically performed at 3 months. Primary end point was the difference in the proportion of covered struts at 3 months (defined as ≥20 μm of tissue coverage). Secondary end points included differences in percentage of uncovered struts (0 μm coverage), mean strut coverage thickness, and malapposed struts' coverage proportion. Major adverse cardiac events (cardiac death, myocardial infarction, target lesion revascularization, and definite or probable stent thrombosis) at 12 months were also evaluated.70 patients were included. At 3 months, a consistent and significantly higher strut coverage rate (≥20 μm) was observed in PF-SES as compared to BP-SES, both for well apposed (87.3% versus 79.1%, p 0.001) and malapposed struts (50.4% vs 37.8%, p 0.00). Uncoverage rate (0 μm) was also significantly lower for the PF-SES (3.1% vs 5.3%, p 0.001). There were no differences in clinical endpoints.The probucol coated non-polymeric ultra-thin strut sirolimus eluting stent showed a significantly better early strut coverage at 3 months.
- Published
- 2021
48. Clinical follow-up of long nontapered sirolimus-eluting coronary stent in real-world patients with de novo lesions. The Billar registry
- Author
-
Enric Domingo Ribas, Juan Casanova-Sandoval, Imanol Otaegui, Ramón Calviño Santos, Javier León Jiménez, Xavier Carrillo Suarez, Alfonso Torres, Juan Francisco Cara Muñoz, Josep Guindo, Leire Andraka, and Mónica Fuertes, Bruno García del Blanco, Ramiro Trillo Nouche, Joan Antoni Gómez, Raymundo Ocaranza Sánchez, and Juan E. Sánchez
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Coronary angioplasty ,Malalties coronàries ,Nontapered stents ,Surgery ,Pròtesis de Stent ,Coronary diseases ,Sirolimus ,Coronary stent ,Medicine ,Drug-eluting stent ,Cardiology and Cardiovascular Medicine ,business ,Stents (Surgery) ,medicine.drug - Abstract
Introduction and objectives: Coronary lesions with stent overlapping are associated with higher neointimal proliferation that leads to more restenosis. Furthermore, the tapering of coronary arteries is a major challenge when treating long coronary lesions. This study attempted to assess the safety and clinical level of performance of long nontapered sirolimus-eluting coronary stent systems (> 36 mm) to treat long and diffused de novo coronary lesions in real-world scenarios. Methods: This was a prospective, non-randomized, multicentre study that included 696 consecutive patients treated with the long nontapered BioMime sirolimus-eluting coronary stent system in long and diffused de novo coronary lesions. The safety endpoint was major adverse cardiovascular events defined as a composite of cardiac death, myocardial infarction, clinically driven target lesion revascularization, stent thrombosis, and major bleeding at the 12-month follow-up. Results: Of a total of 696 patients, 38.79% were diabetic. The mean age of all the patients was 64.6 ± 14 years, and 80% were males. The indication for revascularization was acute coronary syndrome in 63.1%. A total of 899 lesions were identified out of which 742 were successfully treated with long BioMime stents (37 mm, 40 mm, 44 mm, and 48 mm). The cumulative incidence of major adverse cardiovascular events was 8.1% at the 12-month follow-up including cardiac death (2.09%), myocardial infarction (1.34%), and total stent thrombosis (0.5%). Conclusions: This study confirms the safety and good performance of long nontapered BioMime coronary stents to treat de novo coronary stenosis. Therefore, it can be considered a safe and effective treatment for long and diffused de novo coronary lesions in the routine clinical practice.
- Published
- 2021
49. Chromosomal instability mediates immune exclusion and response to cytotoxic chemotherapy in colorectal liver metastases
- Author
-
John N. Primrose, Soumya C Iyer, Mark Talamonti, Mitchell C. Posner, Michael I. D’Angelica, Ralph R. Weichselbaum, Liam F. Spurr, Carlos A. Martinez, Enric Domingo, Sean P. Pitroda, Sian Alexandra Pugh, Philip P. Connell, Tim Maughan, and John Bridgewater
- Subjects
Tumor microenvironment ,Bladder cancer ,business.industry ,Colorectal cancer ,medicine.medical_treatment ,Aneuploidy ,medicine.disease ,Radiation therapy ,Pathogenesis ,Immune system ,Chromosome instability ,Cancer research ,medicine ,business - Abstract
The genomic drivers of immune exclusion in colorectal cancer liver metastases (CRCLM) remain poorly understood. Chromosomal instability (CIN), resulting in aneuploidy and genomic rearrangements, is the central pathway of mismatch repair-proficient colorectal cancer pathogenesis; however, it is unknown whether CIN impacts the outcomes of patients with limited spread of CRCLM treated with curative intent cytotoxic chemotherapy and surgery. Herein, we examined the relationship between CIN and the molecular subtypes of CRCLM, immune signaling, treatment sensitivity, and patient outcomes in three independent CRCLM patient cohorts. We established that a previously developed 70-gene CIN signature (CIN70) is a reliable measure of CIN, encompassing features of both aneuploidy and cellular proliferation. We demonstrated that tumors with the canonical subtype of CRCLM exhibit elevated levels of CIN and aneuploidy. Genomically unstable tumors were associated with an immune-depleted tumor microenvironment, and patients with genomically unstable tumors were at increased risk for disease progression in adverse metastatic sites, resulting in poor progression-free and overall survival. However, high-CIN tumors were particularly susceptible to DNA-damaging chemotherapies, including topoisomerase inhibitors, as well as radiation therapy. Treatment with genotoxic agents depleted CIN-rich cell populations, which resulted in a concomitant increase in intratumoral CD8+ T-cells in patients with primary rectal, breast, and bladder cancer. Taken together, we propose a mechanistic explanation for why cytotoxic chemotherapy can augment anti-tumor immunity and improve outcomes in patients with genomically unstable cancers.
- Published
- 2021
- Full Text
- View/download PDF
50. Inhibition of WEE1 Is Effective in
- Author
-
Jenny F, Seligmann, David J, Fisher, Louise C, Brown, Richard A, Adams, Janet, Graham, Philip, Quirke, Susan D, Richman, Rachel, Butler, Enric, Domingo, Andrew, Blake, Emma, Yates, Michael, Braun, Fiona, Collinson, Rob, Jones, Ewan, Brown, Emma, de Winton, Timothy C, Humphrey, Mahesh, Parmar, Richard, Kaplan, Richard H, Wilson, Matthew, Seymour, and Timothy S, Maughan
- Subjects
Male ,Cell Cycle Proteins ,Pyrimidinones ,Middle Aged ,Protein-Tyrosine Kinases ,Prognosis ,Survival Rate ,Antineoplastic Combined Chemotherapy Protocols ,Mutation ,Quality of Life ,ras Proteins ,Humans ,Pyrazoles ,Female ,Enzyme Inhibitors ,Neoplasm Metastasis ,Tumor Suppressor Protein p53 ,Colorectal Neoplasms ,Watchful Waiting ,Follow-Up Studies - Abstract
Outcomes inPatients with newly diagnosed mCRC were registered into FOCUS4 and tested forFOCUS4-C was conducted between April 2017 and Mar 2020 during which time 718 patients were registered; 247 (34%) wereIn this phase II randomized trial, adavosertib improved PFS compared with AM and demonstrates potential as a well-tolerated therapy for
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.